Previous 10 | Next 10 |
WATERTOWN, Mass., April 11, 2023 (GLOBE NEWSWIRE) -- Kymera Therapeutics, Inc. (NASDAQ: KYMR), a clinical-stage biopharmaceutical company advancing targeted protein degradation to deliver novel small molecule protein degrader medicines, will report first quarter 2023 financial results on May 4, 2...
2023-04-09 13:19:32 ET InvestorPlace - Stock Market News, Stock Advice & Trading Tips Generally speaking, biotech stocks to buy offer investors an excellent opportunity for significant upside success. According to Grand View Research, the global market size for the industry ...
Kymera Therapeutics, Inc. (KYMR) Q4 2022 Earnings Conference Call February 23, 2023 8:30 AM ET Company Participants Bruce Jacobs - Chief Financial Officer Nello Mainolfi - Founder & Chief Executive Officer Jared Gollob - Chief Medical Officer Conference Call ...
Kymera Therapeutics press release ( NASDAQ: KYMR ): Q4 GAAP EPS of -$0.60 beats by $0.03 . Revenue of $16.1M (+5.4% Y/Y) misses by $4.56M . As of December 31, 2022, Kymera had approximately $559.5M in cash, cash equivalents, and investments. Kymera expects that its...
WATERTOWN, Mass., Feb. 01, 2023 (GLOBE NEWSWIRE) -- Kymera Therapeutics, Inc. (NASDAQ: KYMR), a clinical-stage biopharmaceutical company advancing targeted protein degradation to deliver novel small molecule protein degrader medicines, will report fourth quarter and full year 2022 financial resul...
X-Chem, the provider of innovative solutions in early-stage drug discovery, has announced the expansion of its collaboration with Kymera Therapeutics ( NASDAQ: KYMR ). With the expanded agreement, X-Chem will serve as the primary provider of DNA-encoded library-based screening ser...
X-Chem , the leading provider of innovative solutions in early-stage drug discovery, today announced the expansion of its collaboration with Kymera Therapeutics, Inc. (NASDAQ: KYMR). With the expanded agreement, X-Chem will serve as the primary provider of DNA-encoded library (DEL)-based sc...
Summary Kymera Therapeutics, Inc.'s KT-474 HS/AD data de-risked the IRAK4 protein degradation platform, as did Sanofi's partnering. However, more differentiating data seems to be needed in these indications and with IRAK4 inhibitors. I also wish to see more data from self-owned prod...
WATERTOWN, Mass., Jan. 10, 2023 (GLOBE NEWSWIRE) -- Kymera Therapeutics, Inc. (NASDAQ: KYMR), a clinical-stage biopharmaceutical company advancing targeted protein degradation (TPD) to deliver novel small molecule protein degrader medicines, today announced its research, development and corporate...
WATERTOWN, Mass., Jan. 03, 2023 (GLOBE NEWSWIRE) -- Kymera Therapeutics, Inc. (NASDAQ: KYMR), a clinical-stage biopharmaceutical company advancing targeted protein degradation to deliver novel small molecule protein degrader medicines, today announced the Company will present at the 41 st Ann...
News, Short Squeeze, Breakout and More Instantly...
Kymera Therapeutics Inc. Company Name:
KYMR Stock Symbol:
NASDAQ Market:
Kymera Therapeutics Inc. Website:
2024-07-12 19:30:00 ET Stock Traders Daily has produced this trading report using a proprietary method. This methodology seeks to optimize the entry and exit levels to maximize results and limit risk, and it is also applied to Index options, ETFs, and futures for our subscribers. This...
2024-07-09 13:30:00 ET Shares of Kymera Therapeutics (NASDAQ: KYMR) were soaring 18.4% higher as of 11:28 a.m. ET on Tuesday. The big jump came after the clinical-stage biopharmaceutical company announced on Monday that its partner, Sanofi , plans to expand the ongoing phase 2 s...
WATERTOWN, Mass., July 09, 2024 (GLOBE NEWSWIRE) -- Kymera Therapeutics, Inc. (NASDAQ: KYMR), a clinical-stage biopharmaceutical company advancing a new class of small molecule medicines using targeted protein degradation (TPD), today announced that the Company will participate in a fireside ...